* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Notes from Round Table 35 January 27, 2016
Survey
Document related concepts
Neuropharmacology wikipedia , lookup
Pharmacognosy wikipedia , lookup
Compounding wikipedia , lookup
Drug interaction wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Prescription costs wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Drug design wikipedia , lookup
Drug discovery wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Monoclonal antibody wikipedia , lookup
Transcript
Notes from Round Table 35 January 27, 2016 Topic: Analytical Challenges Related to Antibody-drug Conjugates Characterization and Specifications Facilitator: Oscar Salas-Solano, Seattle Genetics, Inc. Scribe: Brian DiPaolo, AbbVie, Inc. Scope: Antibody-drug conjugates (ADCs) are becoming increasingly important therapeutic agents. ADCs are manufactured through the chemical linkage of a potent cytotoxic drug to a monoclonal antibody (mAb). As a result, ADCs leverage the selectivity of monoclonal antibodies (mAb) for targeted delivery of the cytotoxic drug while minimizing exposure to normal tissues. Generally, the conjugation process generates more complex and heterogeneous ADC structures than the corresponding parent mAb. ADC’s heterogeneity presents challenges to both the analysis of product quality attributes and setting of specifications. This table will discuss strategies to advance ADC characterization and facilitate the setting of specifications. Notes: BULLET POINTS FOR DISCUSSION: 1. The selection of appropriate analytical methods for a specific ADC depends on the properties of the drug-linker and the conjugation site (inter-chain cysteines, lysines, engineered cysteines, Fc glycans, etc.). a. There is significant variability here, depending on the drug-linker and its properties. 2. What quality attributes are relevant for ADCs? a. DAR (drug-antibody ratio), even for site-specific ADCs is an essential quality attribute. i. DAR profile = safety profile that was tested in clinic ii. It was acknowledged that manufacturing ADCs with a consistent DAR profile is essential iii. It is important to monitor what level of unconjugated product (both free monoclonal and free drug/payload) is found in the ADC. It was acknowledged that some manufacturing processes will have further purification steps to remove these impurities. iv. Developing a robust stability program is vital for monitoring the long-term quality of the ADC. For example, is degradation seen? Is there a risk that the ADC could "fall apart" over time? 1. Is "over-conjugation" a possibility for an ADC? Would this have an impact on the stability profile of the ADC? 2. It was acknowledged that ADCs are generally put through same stability program as a naked antibody. b. Aggregation, subvisible particles due to hydrophobicity 3. What novel methodologies can be applied to advance the physicochemical and biological characterization of ADCs? a. The concept of leveraging in-process controls as part of overall control strategy was discussed. b. Mass Spectrometry was discussed as a very important tool to characterize ADCs. c. A general discussion topic was around handling very toxic material on general QC equipment. i. You may only have a few labs that could handle these materials. ii. Dedicated labs are an option. iii. Robust cleaning is necessary. d. The topic of whether there are good analytical methods to detect product variants, especially when these attributes could be hidden by the drug conjugation process. e. Peptide mapping is helpful -- higher order structure -- to determine what happens to antibody after conjugation. f. You will likely need to develop analytical methodology to detect degradation products. Other discussion points - - It's essential to know how much payload is in the drug. It was acknowledged that you will likely need to perform some nonclinical studies on your payload alone, which will establish a safety profile. From a weight/weight basis, the amount of free drug in the product is likely very minimal (below ICH threshold for safety). A FDA participant mentioned that the Toxicology Reviewers are likely to look closely at what is going on in clinical studies throughout industry. o For example, they could request a study to start at a lower dose because what they have seen on other programs. For drugs with highly active payloads, resulting in low therapeutic doses, o Studies for compatability with infusion sets are difficult due to further dilution in saline o Developing analytical methods with the appropriate sensitivity level might be difficult. - - It was acknowledged that some characteristics can be analyzed at mAb rather than at the ADC. If you establish a robust manufacturing process (with control) for the mAb, can you avoid repeating characterization on the conjugated ADC? o The participants felt that this would likely be a case-by-case decision. It was mentioned that, when you're generating reference standards, make sure you're already thinking about criteria for potency (e.g., binding ELISA). o If there isn't transparency in providing reference standard information, there could be difficulty in piecing the analytical (e.g., potency) story together.